Radiation injury
diseaseOn this page
Also known as Injuries, radiationinjury, radiationradiation sicknessradiation Sicknessesradiation syndromeradiation syndromessickness, radiationSicknesses, radiationsyndrome, radiationsyndromes, radiation
Summary
Radiation injury (MONDO:0043458) is a disease with 58 GWAS associations across 14 studies and 33 clinical trials. Top therapeutic interventions include bevacizumab, donepezil, and pentoxifylline. A subtype of injury — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 58
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | radiation injury |
| Mondo ID | MONDO:0043458 |
| MeSH | D011832 |
| Is cancer (heuristic) | no |
Also known as: Injuries, radiation · injury, radiation · radiation injury · radiation sickness · radiation Sicknesses · radiation syndrome · radiation syndromes · sickness, radiation · Sicknesses, radiation · syndrome, radiation · syndromes, radiation
Data availability: 58 GWAS associations (14 studies).
Disease family
This is a subtype of injury. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: injury › radiation injury
Related subtypes (9): ischemia reperfusion injury, bone fracture, acute lung injury, spinal injury, burn, ankle injury, nervous system injury, frostbite, head injury
Genetics & variants
GWAS landscape
58 GWAS associations across 14 studies. Top hits map to 31 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs72725854 | 4e-26 | PCAT1 | A | 0.56 |
| chr8:128077146 | 2e-14 | G | 0.41 | |
| rs1061660 | 1e-07 | SEC14L2 | C | 0.09 |
| rs73039018 | 1e-07 | ZNF607 - ZNF573 | A | 0.1 |
| rs111794065 | 2e-07 | HAR1A - MIR124-3 | A | 0.16 |
| rs137992872 | 2e-07 | TCF20 | A | 0.21 |
| rs1044281 | 2e-07 | BBOX1-AS1, BBOX1 | T | 0.11 |
| rs187638451 | 2e-07 | DSCAM | ? | |
| rs8054933 | 4e-07 | MPHOSPH6-DT - CDH13 | A | 0.09 |
| rs2126976 | 4e-07 | ZNF793 | T | 0.09 |
| rs9885106 | 6e-07 | GMCL2 - HNRNPAB | C | 0.09 |
| rs7207494 | 9e-07 | HS3ST3A1 | C | 0.12 |
| rs7840941 | 9e-07 | ATP6V0D2 - SLC7A13 | C | 0.08 |
| rs7096412 | 1e-06 | LINC02667 - MGMT | A | 0.51 |
| rs6458543 | 1e-06 | ADGRF1 - TNFRSF21 | T | 0.22 |
| rs713555 | 1e-06 | ZNF831 | A | 0.09 |
| rs141610705 | 2e-06 | RB1 - CYSLTR2 | G | 0.19 |
| rs11682790 | 2e-06 | LINC02991 - NDUFA10 | T | 0.08 |
| rs17663419 | 2e-06 | FAM135B | A | 0.15 |
| rs4842187 | 2e-06 | FCN2 - FCN1 | C | 0.18 |
| rs7246871 | 2e-06 | ZNF627 | G | 0.18 |
| rs10776839 | 2e-06 | RXRA - COL5A1 | T | 0.08 |
| rs139806224 | 2e-06 | UQCC4 - PERCC1 | A | 0.35 |
| rs13204987 | 3e-06 | MAN1A1 - MIR3144 | A | 0.09 |
| rs115306657 | 3e-06 | RNA5SP173 - NDUFB5P1 | A | 0.31 |
| rs144453545 | 3e-06 | BEND4 | C | 0.28 |
| rs116951625 | 3e-06 | TSC22D1 | A | 0.27 |
| rs72745994 | 3e-06 | LINC01418 | T | 0.23 |
| rs67480819 | 3e-06 | DUXAP11 - APOOP5 | G | 0.16 |
| rs141164482 | 3e-06 | HMGB3P6 - PBX1 | A | 0.16 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90476293 | Verma A | 2024 | 6,356 | 438,261 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436905 | Zhou W | 2018 | 3,130 | 403,295 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90476292 | Verma A | 2024 | 2,196 | 117,731 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480647 | Verma A | 2024 | 2,196 | 117,731 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90482583 | Verma A | 2024 | 467 | 58,925 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651960 | Liu TY | 2025 | 289 | 232,139 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90244175 | Naderi E | 2022 | 0 | 0 | Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer. |
| GCST90244176 | Naderi E | 2022 | 0 | 0 | Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer. |
| GCST90244177 | Naderi E | 2022 | 0 | 0 | Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer. |
| GCST90244178 | Naderi E | 2022 | 0 | 0 | Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 4 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 45 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 26 |
| low_freq (0.01-0.05) | 23 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 27 |
| intergenic_variant | 16 |
| 3_prime_UTR_variant | 4 |
| unknown | 1 |
| missense_variant | 1 |
| non_coding_transcript_exon_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs72725854 | 8 | 127062570 | A>G,T | 0.014 | intron_variant | PCAT1 | 4e-26 | Tier 4: intronic/intergenic |
| chr8:128077146 | 0.024 | 2e-14 | Tier 4: intronic/intergenic | |||||
| rs1061660 | 22 | 30423640 | T>A,C | 0.289 | 3_prime_UTR_variant | SEC14L2 | 1e-07 | Tier 2: splice/UTR |
| rs73039018 | 19 | 37726993 | C>A | 0.18 | intergenic_variant | ZNF607 - ZNF573 | 1e-07 | Tier 4: intronic/intergenic |
| rs111794065 | 20 | 63177878 | G>A,C | 0.118 | intron_variant | HAR1A - MIR124-3 | 2e-07 | Tier 4: intronic/intergenic |
| rs137992872 | 22 | 42246837 | G>A,T | 0.069 | intron_variant | TCF20 | 2e-07 | Tier 4: intronic/intergenic |
| rs1044281 | 11 | 27127700 | C>T | 0.126 | 3_prime_UTR_variant | BBOX1-AS1, BBOX1 | 2e-07 | Tier 2: splice/UTR |
| rs187638451 | 21 | 40492554 | A>T | intron_variant | DSCAM | 2e-07 | Tier 4: intronic/intergenic | |
| rs8054933 | 16 | 82452312 | C>A | 0.45 | intergenic_variant | MPHOSPH6-DT - CDH13 | 4e-07 | Tier 4: intronic/intergenic |
| rs2126976 | 19 | 37540031 | C>A,T | 0.23 | 3_prime_UTR_variant | ZNF793 | 4e-07 | Tier 2: splice/UTR |
| rs9885106 | 5 | 178192862 | T>A,C,G | 0.363 | intron_variant | GMCL2 - HNRNPAB | 6e-07 | Tier 4: intronic/intergenic |
| rs7207494 | 17 | 13514792 | T>C | 0.215 | intron_variant | HS3ST3A1 | 9e-07 | Tier 4: intronic/intergenic |
| rs7840941 | 8 | 86188278 | A>C,T | 0.469 | intron_variant | ATP6V0D2 - SLC7A13 | 9e-07 | Tier 4: intronic/intergenic |
| rs7096412 | 10 | 129046176 | G>A | 0.013 | intron_variant | LINC02667 - MGMT | 1e-06 | Tier 4: intronic/intergenic |
| rs6458543 | 6 | 47157706 | C>T | 0.04 | intergenic_variant | ADGRF1 - TNFRSF21 | 1e-06 | Tier 4: intronic/intergenic |
| rs713555 | 20 | 59258463 | G>A,C,T | 0.291 | 3_prime_UTR_variant | ZNF831 | 1e-06 | Tier 2: splice/UTR |
| rs141610705 | 13 | 48607282 | A>G | 0.071 | intergenic_variant | RB1 - CYSLTR2 | 2e-06 | Tier 4: intronic/intergenic |
| rs11682790 | 2 | 239733876 | G>A,C,T | 0.254 | intergenic_variant | LINC02991 - NDUFA10 | 2e-06 | Tier 4: intronic/intergenic |
| rs17663419 | 8 | 138244251 | G>A | 0.06 | intron_variant | FAM135B | 2e-06 | Tier 4: intronic/intergenic |
| rs4842187 | 9 | 134891589 | T>C | 0.043 | intergenic_variant | FCN2 - FCN1 | 2e-06 | Tier 4: intronic/intergenic |
| rs7246871 | 19 | 11565401 | A>G | 0.04 | intergenic_variant | ZNF627 | 2e-06 | Tier 4: intronic/intergenic |
| rs10776839 | 9 | 134525462 | G>C,T | 0.441 | intron_variant | RXRA - COL5A1 | 2e-06 | Tier 4: intronic/intergenic |
| rs139806224 | 16 | 1422881 | G>A | 0.016 | intergenic_variant | UQCC4 - PERCC1 | 2e-06 | Tier 4: intronic/intergenic |
| rs13204987 | 6 | 119612984 | G>A | 0.186 | intron_variant | MAN1A1 - MIR3144 | 3e-06 | Tier 4: intronic/intergenic |
| rs115306657 | 4 | 179368528 | G>A | 0.025 | intergenic_variant | RNA5SP173 - NDUFB5P1 | 3e-06 | Tier 4: intronic/intergenic |
| rs144453545 | 4 | 42120272 | T>C | 0.022 | missense_variant | BEND4 | 3e-06 | Tier 1: coding |
| rs116951625 | 13 | 44522074 | G>A,C | 0.023 | intron_variant | TSC22D1 | 3e-06 | Tier 4: intronic/intergenic |
| rs72745994 | 15 | 81927045 | C>T | 0.034 | intergenic_variant | LINC01418 | 3e-06 | Tier 4: intronic/intergenic |
| rs67480819 | 16 | 59677655 | A>G | 0.069 | intergenic_variant | DUXAP11 - APOOP5 | 3e-06 | Tier 4: intronic/intergenic |
| rs141164482 | 1 | 164500528 | G>A | 0.048 | intron_variant | HMGB3P6 - PBX1 | 3e-06 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 18 |
| PHASE3 | 6 |
| PHASE2 | 6 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00725244 | PHASE4 | COMPLETED | Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias |
| NCT05607927 | PHASE3 | NOT_YET_RECRUITING | PE-Bacon for Late Complications of Chronic Radiation-induced Rectal Injury |
| NCT06888817 | PHASE3 | RECRUITING | Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases |
| NCT00134628 | PHASE3 | TERMINATED | Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries |
| NCT01334931 | PHASE3 | COMPLETED | Use of Large Field of View During Image Acquisition for Coronary Angiography |
| NCT02985164 | PHASE3 | COMPLETED | Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography |
| NCT04059809 | PHASE2/PHASE3 | COMPLETED | Photobiomodulation for Breast Cancer Radiodermatitis |
| NCT04818099 | PHASE3 | UNKNOWN | Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy |
| NCT00001437 | PHASE2 | COMPLETED | Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis |
| NCT02104271 | PHASE2 | COMPLETED | Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. |
| NCT02478255 | PHASE2 | COMPLETED | Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment |
| NCT03208413 | PHASE2 | UNKNOWN | The Therapeutic Effect of Thalidomide in RI |
| NCT03907371 | PHASE2 | UNKNOWN | The Effect of Donepezil in Radiotherapy-related Cognitive Impairment. |
| NCT04152681 | PHASE2 | UNKNOWN | Effect and Safety of Apatinib on Radiation-Induced Brain Injury |
| NCT07231588 | EARLY_PHASE1 | RECRUITING | Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation |
| NCT06325982 | Not specified | RECRUITING | Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury |
| NCT06875583 | Not specified | RECRUITING | The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial |
| NCT07552883 | Not specified | NOT_YET_RECRUITING | Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis |
| NCT00001523 | Not specified | COMPLETED | Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation |
| NCT00745641 | Not specified | WITHDRAWN | Abdominal Computed Tomography and the Blood Reactive Oxygen Species Level |
| NCT00760409 | Not specified | COMPLETED | Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI |
| NCT00815230 | Not specified | WITHDRAWN | Effect of Cardiac Computed Tomography Angiography on the Blood Reactive Oxygen Species Level |
| NCT02152722 | Not specified | UNKNOWN | Breath Test for Biomarkers in Humans Receiving Total Body Irradiation |
| NCT02212964 | Not specified | COMPLETED | Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2* |
| NCT02425215 | Not specified | TERMINATED | HBOT Late Radiation Tissue Injury |
| NCT02725840 | Not specified | COMPLETED | Breast Cancer Lung Late Effects |
| NCT02972736 | Not specified | COMPLETED | RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study |
| NCT03660618 | Not specified | TERMINATED | LSFG-SKIN, Laser Speckle Flowgraphy |
| NCT03667859 | Not specified | COMPLETED | Vaginal Elasticity Assessment Before and After Brachytherapy/Pelvic Radiation |
| NCT03961217 | Not specified | COMPLETED | Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes |
| NCT04067310 | Not specified | COMPLETED | Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis. |
| NCT05063773 | Not specified | UNKNOWN | Novel Wireless Mixed Reality Headset for Image Guidance in Cardiac Catheterization Laboratory |
| NCT07422168 | Not specified | COMPLETED | Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 1 |
| DONEPEZIL | 4 | 1 |
| PENTOXIFYLLINE | 4 | 1 |
| VORTIOXETINE | 4 | 1 |
| TROLAMINE | 2 | 1 |
Related Atlas pages
- Drugs: Bevacizumab, Donepezil, Pentoxifylline, Vortioxetine